Author

H. Ploegh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Organism:yeast· 1

Frequent Co-Authors

N. Pishesha· 3 shared A. C. Williams· 1 shared A. Eaton· 1 shared A. J. B. Kreutzberger· 1 shared A. J. Quartararo· 1 shared A. Loas· 1 shared A. R. Loftis· 1 shared A. Saminathan· 1 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

N. Pishesha

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism

S. Luo, J. Zhang, A. J. B. Kreutzberger, A. Eaton, R. J. Edwards, C. Jing, H.-Q. Dai, G. D. Sempowski, K. Cronin, R. Parks, A. Y. Ye, K. Mansouri, M. Barr, N. Pishesha, A. C. Williams, , F. W. Alt

The paper describes a humanized antibody, SP1-77, that neutralizes all SARS-CoV-2 variants by blocking membrane fusion instead of ACE2 receptor binding.

bioRxiv · Jun 26, 2022 · PreprintImmunology

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL and Prevent Obesity

R. Deshycka, V. Sudaryo, N.-J. Huang, Y. Xie, L. Y. Smeding, M. K. Choi, H. Ploegh, H. Lodish, N. Pishesha

This study develops engineered red blood cells expressing a PCSK9 inhibitor to lower LDL and prevent obesity in mice.

bioRxiv · Nov 2, 2020Bioengineering

Erythrocyte-targeted immunomodulatory antigens enabled by in vivo selection of D-peptides

A. R. Loftis, G. Zhang, C. Backlund, A. J. Quartararo, N. Pishesha, C. K. Schissel, D. Garafola, A. Loas, R. J. Collier, H. Ploegh, D. J. Irvine, B. L. Pentelute

The paper identifies a D-peptide that targets murine erythrocytes and reduces anti-drug antibody responses when conjugated to therapeutic proteins.

bioRxiv · Jul 15, 2020 · PreprintBioengineering

A nanobody suite for yeast scaffold nucleoporins provides details of the Nuclear Pore Complex structure

S. A. Nordeen, K. R. Andersen, K. E. Knockenhauer, J. R. Ingram, H. Ploegh, T. U. Schwartz

The paper develops a set of nanobodies to study yeast nuclear pore complex subcomplexes, revealing their structures and accessible surfaces.

bioRxiv · Jun 19, 2020Biochemistry